Close Menu

diabetes

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

Centene will contribute up to $100 million over 10 years to fund research into Alzheimer's disease, breast cancer, diabetes, and obesity at WashU.

After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.